Cyclerion Therapeutics, Inc.

( )
CYCN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.14%144.520.7%$923.44m
PFEPfizer Inc. -0.82%37.490.9%$784.14m
BMYBristol-Myers Squibb Co. -0.20%60.651.0%$655.99m
MRKMerck & Co., Inc. -0.48%78.290.7%$620.46m
ABBVAbbVie, Inc. -0.07%84.251.9%$591.38m
LLYEli Lilly & Co. 0.53%143.551.1%$509.63m
AZNAstraZeneca Plc -0.48%52.191.2%$198.36m
NVSNovartis AG -0.12%85.690.2%$145.24m
GSKGlaxoSmithKline Plc -0.39%36.040.2%$133.53m
NVONovo Nordisk A/S 0.59%71.200.1%$70.39m
RGENRepligen Corp. 2.22%172.497.1%$63.83m
PRAXPraxis Precision Medicines, Inc. 1.84%27.750.0%$63.55m
RPRXRoyalty Pharma Plc -0.45%40.090.2%$57.64m
SNYSanofi -0.52%49.880.2%$50.07m
AMAGAMAG Pharmaceuticals, Inc. 0.00%13.6422.1%$45.46m

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. Its product pipeline includes several sGC stimulators, a small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate (cGMP). The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.